Industry Insights Seminar Series: Exosome-based therapies for the treatment of rare genetic diseases

January's IISS will feature Dr  David Lowe - VP Research, EVOX.

Talk title: Exosome-based therapies for the treatment of rare genetic diseases

Abstract: 

Exosomes are extracellular vesicles (EVs) that are produced by almost all cells as part of normal physiology and act as naturally-occurring cellular messengers, transporting proteins and nucleic acids as a form of intercellular communication. At Evox we are engineering exosomes to enable specific loading of therapeutic proteins and nucleic acids, with the aim of using these engineered exosomes as potential therapies in inherited metabolic diseases, such as phenylketonuria (PKU) and arginosuccinic aciduria (ASA). By engineering exosome-associated proteins, we can potentially use exosomes to replace mutated proteins in such diseases, either through direct protein replacement or through the deliver of mRNA to target cells.

To register for this talk, click here

For more information on the Industry Insight Seminar Series, click here

These events are usually in person at the BioEscalator. However, due to Covid-19, these seminars will be given virtually. Once back in person there will be limited in-person tickets for BioEscalator tenants, please contact Elodie Siney/reception if you would like to secure an in-person place.

Please contact either Sheena Lee or the BioEscalator if you have any questions.

If you have an industry partner you would like to invite to speak, please contact Sheena Lee.